(VPH: CSE) (VPHIF: OTCQB) (VP2: FSE)
Why Valeo Pharma?
- Commercial stage revenue generating Canadian pharmaceutical company
- Approaching EBITDA positive in coming months
- 9 products currently marketed ($40M. estimated peak sales / year)
- 7 additional products in pipeline ($45M. estimated peak sales / year)
- In-license business model, no development or clinical risk
- $1.5M in quarterly revenue ending July 31, 2020
- $5.26M in revenue for 9 months ending July 31, 2020
What Exactly Does Valeo Pharma Do?
- Acquires Canadian rights to commercial stage, innovative and proprietary drugs
- Commercializes innovative prescription products in Canada
- Focused on Neurodegenerative Diseases, Oncology and Hospital Specialty Products
- Internally manages portfolio through all stages of commercialization
Highlights of MDBriefCase Newsletter Comparing Hesperidin and Vitamin C for COVID-19
- Growing body of research suggests Hesperidin may interfere with SARS-CoV-2 infection process
- Hesperidin may help against Covid-19 viral replication
- Hesperidin is a potent antioxidant with anti-inflammatory activity that may help in controlling cytokine storm
Click below to read in its entirety.
Hub On AGORACOM / Corporate Profile
FULL DISCLOSURE: Valeo Pharma is an advertising client of AGORA Internet Relations Corp.
Tags: BioSyent Inc., CSE, HLS Therapeutics, investment, Knight Therapeutics, Medexus Pharmaceuticals, pharma, pharma stocks, Redesca, small cap, small cap pharma, stocks, tsx